Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis is a fatal CNS neurodegenerative disease. Despite intensive
research, current management of amyotrophic lateral sclerosis remains suboptimal from …
research, current management of amyotrophic lateral sclerosis remains suboptimal from …
Non-neuronal cells in amyotrophic lateral sclerosis—from pathogenesis to biomarkers
The prevailing motor neuron-centric view of amyotrophic lateral sclerosis (ALS)
pathogenesis could be an important factor in the failure to identify disease-modifying therapy …
pathogenesis could be an important factor in the failure to identify disease-modifying therapy …
Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis
The diagnosis of amyotrophic lateral sclerosis can be challenging due to its heterogeneity in
clinical presentation and overlap with other neurological disorders. Diagnosis early in the …
clinical presentation and overlap with other neurological disorders. Diagnosis early in the …
[HTML][HTML] Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
Abstract Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in
which many processes are detected including (neuro) inflammation. Many drugs have been …
which many processes are detected including (neuro) inflammation. Many drugs have been …
[HTML][HTML] Uncompetitive, adduct-forming SARM1 inhibitors are neuroprotective in preclinical models of nerve injury and disease
M Bratkowski, TC Burdett, J Danao, X Wang, P Mathur… - Neuron, 2022 - cell.com
Axon degeneration is an early pathological event in many neurological diseases. The
identification of the nicotinamide adenine dinucleotide (NAD) hydrolase SARM1 as a central …
identification of the nicotinamide adenine dinucleotide (NAD) hydrolase SARM1 as a central …
[HTML][HTML] Plasma and CSF neurofilament light chain in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study
Background: Neurofilament light chain (NfL) is a validated biofluid marker of neuroaxonal
damage with great potential for monitoring patients with neurodegenerative diseases. We …
damage with great potential for monitoring patients with neurodegenerative diseases. We …
[HTML][HTML] Predictors of survival in patients with amyotrophic lateral sclerosis: a large meta-analysis
WM Su, YF Cheng, Z Jiang, QQ Duan, TM Yang… - …, 2021 - thelancet.com
Background The survival time of amyotrophic lateral sclerosis (ALS) is greatly variable and
protective or risk effects of the potential survival predictors are controversial. Thus, we aim to …
protective or risk effects of the potential survival predictors are controversial. Thus, we aim to …
[HTML][HTML] Associations of the circulating levels of cytokines with risk of amyotrophic lateral sclerosis: a Mendelian randomization study
Background Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that is
accompanied by muscle weakness and muscle atrophy, typically resulting in death within 3 …
accompanied by muscle weakness and muscle atrophy, typically resulting in death within 3 …
Whole-genome sequencing reveals that variants in the interleukin 18 receptor accessory protein 3′ UTR protect against ALS
The noncoding genome is substantially larger than the protein-coding genome but has been
largely unexplored by genetic association studies. Here, we performed region-based rare …
largely unexplored by genetic association studies. Here, we performed region-based rare …
[HTML][HTML] Current state and future directions in the diagnosis of amyotrophic lateral sclerosis
M Vidovic, LH Müschen, S Brakemeier, G Machetanz… - Cells, 2023 - mdpi.com
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
loss of upper and lower motor neurons, resulting in progressive weakness of all voluntary …
loss of upper and lower motor neurons, resulting in progressive weakness of all voluntary …